PAMIDRONATE DISODIUM ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C3H9NO7P2.2Na
Molecular Weight	279.0331
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PAMIDRONATE DISODIUM ANHYDROUS

Structure Search

SMILES

[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O

InChI

InChIKey=CEYUIFJWVHOCPP-UHFFFAOYSA-L

InChI=1S/C3H11NO7P2.2Na/c4-2-1-3(5,12(6,7)8)13(9,10)11;;/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11);;/q;2*+1/p-2

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/10342945

Pamidronic acid (Pamidronate Disodium) is a bone resorption inhibitor. The principal pharmacologic action of pamidronate disodium is inhibition of bone resorption. Although the mechanism of antiresorptive action is not completely understood, several factors are thought to contribute to this action. Pamidronate disodium adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment of hypercalcemia, pamidronate disodium inhibits bone resorption apparently without inhibiting bone formation and mineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that pamidronate disodium inhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by various tumors in animal studies. Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Farnesyl diphosphate synthase 28 Target ID: CHEMBL1782 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18327899 \| https://www.ncbi.nlm.nih.gov/pubmed/10620343 \| https://www.ncbi.nlm.nih.gov/pubmed/11160603	Inhibitor 8297		55.9 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Malignant hypercalcemia 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8429	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991
Paget's disease 16 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8429	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991
Osteolytic bone metastases of breast cancer 4 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021113s008lbl.pdf	Primary	Approved 8429	PAMIDRONATE DISODIUM Approved Use Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥50% in at least 50% of patients, and by ≥30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated. Launch Date 1991

C_max

Value	Dose	Analyte	Population
1.92 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9115053/	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.44 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.61 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.73 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
10.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/9115053/	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:		PAMIDRONATE DISODIUM plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	60 mg single, intravenous dose: 60 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	90 mg single, intravenous dose: 90 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
28 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021113s017lbl.pdf	30 mg single, intravenous dose: 30 mg route of administration: Intravenous experiment type: SINGLE co-administered:	PAMIDRONATE DISODIUM unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
5.6 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 5.6 mg/kg, 3 times / day Route: oral Route: multiple Dose: 5.6 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	unhealthy, adult n = 9 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf
120 mg/kg 1 times / day multiple, intravenous Overdose Dose: 120 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Hypocalcemia... AEs leading to discontinuation/dose reduction: Hypocalcemia Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Fever, Hypotension... AEs leading to discontinuation/dose reduction: Fever Hypotension Taste perversion Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	Disc. AE: Interstitial pneumonitis, Hypocalcemia... AEs leading to discontinuation/dose reduction: Interstitial pneumonitis Hypocalcemia Bone pain Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf

AEs

AE	Significance	Dose	Population
Diarrhea	Disc. AE	5.6 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 5.6 mg/kg, 3 times / day Route: oral Route: multiple Dose: 5.6 mg/kg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf	unhealthy, adult n = 9 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 9 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/20-036_med_off_review.pdf
Hypocalcemia	Disc. AE	120 mg/kg 1 times / day multiple, intravenous Overdose Dose: 120 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 120 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Fever	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Hypotension	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Taste perversion	Disc. AE	285 mg/kg 1 times / day multiple, intravenous Overdose Dose: 285 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 285 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Bone pain	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Hypocalcemia	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf
Interstitial pneumonitis	Disc. AE	90 mg/kg 1 times / day single, intravenous Recommended Dose: 90 mg/kg, 1 times / day Route: intravenous Route: single Dose: 90 mg/kg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf	unhealthy, adult n = 182 Health Status: unhealthy Condition: hypercalcemia Age Group: adult Sex: M+F Population Size: 182 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020036s041lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCTN2 66 OCTN1 29	CYP 270 UGT 192

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
OCTN1 29	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/B978178242076750006X	yes
OCTN2 71	inhibitor 3277 Sources: https://www.sciencedirect.com/science/article/pii/B978178242076750006X	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf#page=1 Page: 1.0	no
UGT 192	substrate 3367 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20927lbl.pdf#page=1 Page: 1.0	no

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY553353	https://www.001chemical.com/chem/40391-99-9
3B Scientific (Wuhan) Corp	3B2-1670	http://www.3bsc.com/index/pro_info.php?id=55389
AA Blocks	AA00732G	https://www.aablocks.com/goods/Goods/detail?id=AA00732G
AEchem Scientific Corp., USA	AE032040	http://www.aechemsc.com/info_products/AE032040.php
AK Scientific, Inc. (AKSCI)	2631AH	http://www.aksci.com/item_detail.php?cat=2631AH
Aaron Chemicals	AR0073U8	http://www.aaronchem.com/40391-99-9
Acadechem	ACDS-033198	http://www.acadechemical.com/product/107897
Achemtek	0104-020132	http://www.achemtek.com/40391-99-9
Adooq BioScience	A11685	https://www.adooq.com/pamidronic-acid.html
Angel Pharmatech	AG111246	http://www.angelpharmatech.com/40391-99-9.html
ApexBio Technology	B1807	http://www.apexbt.com/pamidronate.html
Ark Pharm	AK113121	http://www.arkpharminc.com/products/40391-99-9.html
Aurora Fine Chemicals LLC	A13.111.373	http://online.aurorafinechemicals.com/info?ID=A13.111.373
AvaChem Scientific	2606A	http://www.avachem.com/productSearch.asp?2606A
BLD Pharm	BD01332989	http://www.bldpharm.com/products/1159812-33-5.html
BLD Pharm	BD146697	http://www.bldpharm.com/products/40391-99-9.html
BioChemPartner	BCP17709	http://www.biochempartner.com/40391-99-9-BCP17709
BioCrick	BCC4693	http://www.biocrick.com/Pamidronate-BCC4693.html
CSNpharm	CSN11650	https://www.csnpharm.com/products/pamidronic-acid.html
Chem Scene	CS-7787	http://www.chemscene.com/40391-99-9.html
ChemMol	99097528	http://www.chemmol.com/chemmol/99097528.html
Chemspace	CSSB00000052565	https://chem-space.com/CSSB00000052565
Clearsynth	CS-O-30893	http://www.clearsynth.com/en/CSO30893.html
Clearsynth	CS-O-02157	https://www.clearsynth.com/en/CSO02157.html
DC Chemicals	DCAPI1175	http://www.dcchemicals.com//product_show-Pamidronic_acid.html
Debye Scientific	DB-049579	http://www.debyesci.com/cas_40391-99-9.html
Finetech	FT-0630610	http://www.finetechnology-ind.com/prod/detail/pub/40391-99-9.html
Hairui	HR124492	http://www.hairuichem.com/en/product/40391-99-9.html
MedChem Express	HY-B0012	https://www.medchemexpress.com/Pamidronic_acid.html
Molcore	MC553353	https://www.molcore.com/product/40391-99-9
MuseChem	R003777	https://www.musechem.com/product/R003777.html
OChem	7839	http://www.ocheminc.com/index.php?act=psearch&pid=391P999
Selleck Chemicals	S2063	http://www.selleckchem.com/products/pamidronic-acid.html
Sinfoo Biotech	S017541	http://www.sinfoobiotech.com/product/1020939
Smolecule	S591193	https://www.smolecule.com/products/s591193
THE BioTek	bt-308550	https://www.thebiotek.com/product/others/bt-308550
Vesino Industrial Co Ltd	VA11481	http://www.vsnchem.com/goto/product/22804/
abcr GmbH	AB492176	http://www.abcr.com/shop/en/AB492176
eNovation Chemicals	D280137	https://www.enovationchem.com/ProductDetails.asp?ProductID=D280137
eNovation Chemicals	Y1047107	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1047107
iChemical	EBD36833	http://www.ichemical.com/products/40391-99-9.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
mcule	MCULE-4373491291	https://mcule.com/MCULE-4373491291/

PubMed

Title	Date	PubMed
Bisphosphonates in multiple myeloma.	2001	11687178
Bisphosphonates for osteoporosis in people with cystic fibrosis.	2001	11687132
Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.	2001	11596836
[Paget disease or fibrous dysplasia of the radius?--A case report].	2001	11582993
The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma.	2001	11511021
[Vertebral osteoporosis induced by corticoids and cyclosporine ina a patient with Still disease].	2001	11474883
Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis.	2001	11438040
Adjuvant bisphosphonate therapy: the future.	2001 Aug	11544582
Dosing regimens and main adverse events of bisphosphonates.	2001 Aug	11544576
Analysis of skeletal-related events in breast cancer and response to therapy.	2001 Aug	11544572
Effects of a bisphosphonate on the expression of bone specific genes after autogenous free bone grafting in rats.	2001 Aug	11519698
Idiopathic orbital inflammation following intravenous pamidronate.	2001 Aug	11511778
Pamidronate in incident pain due to bone metastases.	2001 Aug	11503631
Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).	2001 Aug	11452173
Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.	2001 Dec	11721169
Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.	2001 Jul	11518261
[Tumor-induced hypercalcemia. Review of bisphosphonate treatment].	2001 Jul	11508158
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.	2001 Jul 15	11454892
Bisphosphonates may be useful in treatment of bone metastases.	2001 Jul 18	11459865
Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.	2001 Jul 19	11463032
Ocular adverse effects of alendronic acid.	2001 Jun	11718170
[Chronic recurrent multifocal osteomyelitis in children: report of 17 cases].	2001 Jun	11446177
[Analgesic effect of Pamidronate on bone pain in patient with hypertrophic pulmonary osteoarthropathy].	2001 Jun	11416808
Disease controlling antirheumatic therapy in spondyloarthropathy.	2001 Jun	11409153
The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate.	2001 Jun	11406740
Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.	2001 May	11683535
[Two cases of effective weekly paclitaxel administration for metastatic breast cancer].	2001 Nov	11729485
Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.	2001 Nov	11719835
Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro.	2001 Nov	11697801
Antibacterial effect of human V gamma 2V delta 2 T cells in vivo.	2001 Nov	11696580
Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens.	2001 Nov 1	11673519
Paget's disease of the spine and its management.	2001 Oct	11718191
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.	2001 Oct	11680835
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.	2001 Oct	11593054
The use of a whole body index with bone scintigraphy to monitor the response to therapy in Paget's disease.	2001 Oct	11567178
Prevention of bone loss and fracture after lung transplantation: a pilot study.	2001 Oct 15	11602851
Hypercalcemia in patients with oral squamous cell carcinoma.	2001 Sep	11642565
Intravenous pamidronate reduces osteoporosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits.	2001 Sep	11603525
Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison.	2001 Sep	11589787
Bisphosphonates for osteoporosis.	2001 Sep	11586803
Isoprenoid biosynthesis. Metabolite profiling of peppermint oil gland secretory cells and application to herbicide target analysis.	2001 Sep	11553758
Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.	2001 Sep	11547843
Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: suggested therapeutic approach.	2001 Sep	11533372
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.	2001 Sep 1	11520816
Trastuzumab and breast cancer.	2001 Sep 27	11575298
Bone loss accompanying medical therapies.	2001 Sep 27	11575293
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.	2001 Sep 27	11575286
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.	2001 Sep 7	11435429
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.	2001 Sep-Oct	11693896
Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia.	2001 Summer	11477309

Patents

Sample Use Guides

In Vivo Use Guide

Moderate Hypercalcemia The recommended dose of pamidronate disodium in moderate hypercalcemia (corrected serum calcium* of approximately 12 to 13.5 mg/dL) is 60 to 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency. Severe Hypercalcemia The recommended dose of pamidronate disodium in severe hypercalcemia (corrected serum calcium* >13.5 mg/dL) is 90 mg given as a SINGLE-DOSE, intravenous infusion over 2 to 24 hours. Longer infusions (i.e., >2 hours) may reduce the risk for renal toxicity, particularly in patients with preexisting renal insufficiency.

Route of Administration: Intravenous

In Vitro Use Guide

BMSCs proliferation was significantly inhibited with 10(−4) M Pamidronic acid (pamidronate) after 72h and 168h, and with 6 × 10(−5) M pamidronate after 168h. Alveolar osteoblasts cultured in osteogenic medium exhibited significantly lower alkaline phosphatase (AP) activities with 6 × 10(−5) M and 10(−4) M pamidronate (39% and 16% of the unsupplemented group) as compared to all lower concentration groups after 168h.

Name

Type

Language

PAMIDRONATE DISODIUM ANHYDROUS

Common Name

English

PHOSPHONIC ACID, (3-AMINO-1-HYDROXYPROPYLIDENE)BIS-, DISODIUM SALT

Common Name

English

PAMIDRONIC ACID DISODIUM SALT [MI]

Common Name

English

PAMIDRONIC ACID DISODIUM SALT

Common Name

English

NSC-722600

Code

English

DISODIUM DIHYDROGEN (3-AMINO-1-HYDROXYPROPYLIDENE)DIPHOSPHONATE

Systematic Name

English

ANHYDROUS PAMIDRONATE DISODIUM

Common Name

English

GCP-23339A

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C443